Throughout their experience of illness and during the course of treatment, a substantial
proportion of cancer patients are prone to develop nutritional and/or metabolic disturbances …

Common treatment methods for malignant tumors include surgery, chemotherapy,
radiotherapy, immunotherapy, targeted therapy, etc., among which chemotherapy plays an …

Background During chemotherapy for multiple myeloma, symptoms include those related to
the disease, as well as adverse effects of the treatment. Few studies have explored the …

Both randomized controlled trials (RCTs) and retrospective studies have shown that a
comprehensive geriatric assessment (CGA) prior to a patient commencing systemic anti …

Background CINV is a frequent adverse response to cancer treatment. There is still much to
learn about the pathophysiology and initiating event of CINV, which necessitates continued …

Background: To establish the role of antiemetic therapy with neurokinin-1 (NK-1) receptor
antagonists (RAs) in Chinese patients associated with cisplatin-base chemotherapy …

Purpose Improvement in the control of delayed chemotherapy-induced nausea and vomiting
(CINV) is needed. There is limited information on antiemetic prophylaxis for patients …

Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects
of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of …

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair
the quality of life of patients with various malignancies ranging from early to end stages. In …

Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a
single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID …